Major Histocompatibility Complex Class I Chain-Related (MICA) STR Polymorphisms in COVID-19 Patients
Metadatos
Afficher la notice complèteAuteur
Gutiérrez Bautista, Juan Francisco; Rodríguez Nicolás, Antonio; Rosales Castillo, Antonio; Jiménez, Pilar; Anderson, Per Olof; López Ruz, Miguel Ángel; López Nevot, Miguel Ángel; Ruiz-Cabello Osuna, FranciscoEditorial
MDPI
Materia
MICA STR polymorphisms MICA SARS-CoV-2 NK cells Innate immunity
Date
2022-06-23Referencia bibliográfica
Gutiérrez-Bautista, J.F... [et al.]. Major Histocompatibility Complex Class I Chain-Related (MICA) STR Polymorphisms in COVID-19 Patients. Int. J. Mol. Sci. 2022, 23, 6979. [https://doi.org/10.3390/ijms23136979]
Patrocinador
Instituto de Salud Carlos III - FEDER funds (European Union) PI 16/00752 B-CTS-410-UGR-20; Junta de Andalucia CTS-143 C-0013-2018Résumé
The SARS-CoV-2 disease presents different phenotypes of severity. Comorbidities, age, and
being overweight are well established risk factors for severe disease. However, innate immunity plays
a key role in the early control of viral infections and may condition the gravity of COVID-19. Natural
Killer (NK) cells are part of innate immunity and are important in the control of virus infection by
killing infected cells and participating in the development of adaptive immunity. Therefore, we
studied the short tandem repeat (STR) transmembrane polymorphisms of the major histocompatibility
complex class I chain-related A (MICA), an NKG2D ligand that induces activation of NK cells, among
other cells. We compared the alleles and genotypes of MICA in COVID-19 patients versus healthy
controls and analyzed their relation to disease severity. Our results indicate that the MICA*A9 allele
is related to infection as well as to symptomatic disease but not to severe disease. The MICA*A9
allele may be a risk factor for SARS-CoV-2 infection and symptomatic disease.